Patents Issued in September 25, 2018
  • Patent number: 10080766
    Abstract: Provided herein are compositions and methods to improve treatment of chronic infections, and reduce, delay, or inhibit formation of biofilms, using specific combinations of aminoglycoside antibiotics and high, localized concentrations of one or more PMF stimulating compounds. These novel methods are easily adapted to clinical settings as toxicity and efficacy of the antibiotics and metabolites used have already been studied in vivo, and as dosing for both the antibiotics and metabolites are known. These approaches and therapeutic methods are also useful with non-metabolic chemicals that induce proton-motive force in bacteria.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: September 25, 2018
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: James J. Collins, Kyle R. Allison, Mark P. Brynildsen
  • Patent number: 10080767
    Abstract: An injectable monophase hydrogel is provided and is made of a reaction mixture of a high molecular weight hyaluronic acid and a low molecular weight hyaluronic acid.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: September 25, 2018
    Assignee: Allergan Industrie SAS
    Inventor: Pierre F. Lebreton
  • Patent number: 10080768
    Abstract: The present invention generally relates to compositions and methods for topical or transdermal delivery. The compositions can be used in a variety of applications. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. The composition can also be applied to a mucosal surface in some instances. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: September 25, 2018
    Assignee: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Patent number: 10080769
    Abstract: Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to an HLA mismatched recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: September 25, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Samuel Strober, Robert Lowsky
  • Patent number: 10080770
    Abstract: The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: September 25, 2018
    Assignee: RegenLab USA LLC
    Inventors: Antoine Turzi, Donald Francois Du Toit
  • Patent number: 10080771
    Abstract: Compositions and methods for generating human epithelial stem cells from induced pluripotent stem cells are disclosed. Also disclosed are methods of using cells so generated in hair transplant procedures.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: September 25, 2018
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Xiaowei Xu, Ruifeng Yang
  • Patent number: 10080772
    Abstract: The invention provides compositions comprising one or more bacterial strains for use in a method of reducing the level of Enterobacteriaceae in the gastrointestinal tract.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: September 25, 2018
    Assignee: 4D Pharma PLC
    Inventors: Laureen Crouzet, Chloe Habouzit, Annick Bernalier-Donadille
  • Patent number: 10080773
    Abstract: A probiotic organism which is capable of proliferation in iron-rich media, an environment which is generally unfavorable to probiotic organisms, is described.
    Type: Grant
    Filed: July 19, 2012
    Date of Patent: September 25, 2018
    Assignee: The University of Bristol
    Inventors: Tristan Cogan, Jenny Bailey
  • Patent number: 10080774
    Abstract: The present invention involves compositions and methods for treating cancer using a mutant adenovirus comprising a polynucleotide encoding a therapeutic polypeptide that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming cells with a wild type retinoblastoma pathway.
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: September 25, 2018
    Assignee: Board of Regents, The University of Texas System
    Inventors: Juan Fueyo, Candelaria Gomez-Manzano, W. K. Alfred Yung, Charles A. Conrad, Frederick F. Lang, Jr.
  • Patent number: 10080775
    Abstract: A peptide having skin-whitening activity is described. The peptide exhibits an excellent skin whitening effect by inhibiting melanogenesis, inhibiting the activity of tyrosinase, inhibiting the expression of melanosis-involved factors, and inhibiting melanosome transfer. The peptide has excellent skin permeability due to the small size thereof. Excellent activity and stability of the foregoing peptide can be very favorably applied to cosmetics.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: September 25, 2018
    Assignee: CAREGEN CO., LTD.
    Inventors: Yong Ji Chung, Eun Mi Kim, Eung-Ji Lee, Jan Di Kim
  • Patent number: 10080776
    Abstract: A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: September 25, 2018
    Assignees: Sapporo Medical University, Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Toshihiko Torigoe, Yoshihiko Hirohashi, Noriyuki Satoh, Kenjiro Kamiguchi, Rena Morita, Satoshi Nishizawa, Akari Takahashi
  • Patent number: 10080777
    Abstract: The invention provides for peptides from syndecan 4 and methods of use therefor. These peptides can inhibit ?6?4 integrin interaction with EGFR, thereby preventing tumor cell growth and tissue invasion, or inhibiting scarring and/or pathologic neovascularization.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: September 25, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventor: Alan Rapraeger
  • Patent number: 10080778
    Abstract: Five tetra peptides corresponding to different active regions of brain derived neurotrophic factor (BDNF) that are neurotrophic and can modulate BDNF signaling in a partial agonist/antagonist way. The peptides offer a therapeutic approach to neural pathologies where BDNF levels are dysregulated.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: September 25, 2018
    Assignee: Research Foundation For Mental Hygiene, Inc.
    Inventors: Khalid Iqbal, Inge Grundke-Iqbal
  • Patent number: 10080779
    Abstract: The invention disclosed herein relates to the field of epidermal repair and skin innate immunity. More particularly, the invention concerns the use of a mix of cytokines to inhibit keratinocyte differentiation, activate skin innate immunity, increase the expression of anti-microbial peptides, and improve epidermal repair. In particular, the invention concerns compositions comprising at least IL-17, TNF? and OSM that can be formulated for topical administration for cosmetic or dermatologic use.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: September 25, 2018
    Assignees: Universite D'Angers, Universite de Poitiers, Bioalternatives SAS
    Inventors: Jean-Claude Lecron, Hughes Gascan, Franck Morel, Sylvie Chevalier, Francois-Xavier Bernard, Katia Boniface, Caroline Diveau
  • Patent number: 10080780
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: September 25, 2018
    Assignee: Shire-NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • Patent number: 10080781
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: September 25, 2018
    Assignee: Shire-NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • Patent number: 10080782
    Abstract: The invention provides compositions containing hemoglobin, particularly PEGylated hemoglobin. The PEGylated hemoglobin molecule is capable of transferring oxygen or carbon monoxide bound thereto to a tissue with which it is in proximity. Exemplary PEGylated hemoglobin formulations of the invention are virally inactivated. Various compositions of the invention include deoxygenated hemoglobin, which may be conjugated with one or more water-soluble polymer. PEGylated hemoglobin includes those species in which the iron atom of the hemoglobin molecule is not bound to oxygen or any other species, and hemoglobin molecules in which a species other than oxygen, e.g., carbon monoxide, is bound to the iron atom. The compositions of the invention are formulated as hypo-, iso- or hypertonic solutions of the PEGylated hemoglobin. The compositions are of use to treat and/or ameliorate disease, injury and insult by providing for the oxygenation of tissues and/organs.
    Type: Grant
    Filed: June 9, 2010
    Date of Patent: September 25, 2018
    Assignee: Prolong Pharmaceuticals, LLC
    Inventors: Abraham Abuchowski, Steven Sloshberg, Keith O'Hare
  • Patent number: 10080783
    Abstract: Lysosomal storage diseases can be successfully treated using intraventricular delivery of the enzyme which is etiologically deficient in the disease. The administration can be performed slowly to achieve maximum effect. Surprisingly, effects are seen on both sides of the blood-brain barrier, making this an ideal delivery means for lysosomal storage diseases which affect both brain and visceral organs.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: September 25, 2018
    Assignee: Genzyme Corporation
    Inventors: James Dodge, Marco A. Passini, Lamya Shihabuddin, Seng H. Cheng
  • Patent number: 10080784
    Abstract: The use of a purine nucleoside phosphorylase or nucleoside hydrolase or a vector encoding expression of one of these enzymes is detailed along with the use of a prodrug cleaved by the purine nucleoside phosphorylase or nucleoside hydrolase for the preparation of a direct injection inhibition of replicating or non-replicating targeted cells. The targeted cells do not normally express the introduced purine nucleoside phosphorylase or nucleoside hydrolase. The enzyme and prodrug are amenable to intermixing and injection as a single dose or as separate injection or administration to the targeted cells. The substance and prodrug efficacy are enhanced through exposure of the targeted cells to X-ray radiation. Administration of a prodrug regardless of administration route to the targeted cells is effective in combination with X-ray radiation therapy to kill or inhibit function of the targeted cells.
    Type: Grant
    Filed: February 20, 2012
    Date of Patent: September 25, 2018
    Assignees: SOUTHERN RESEARCH INSTITUTE, THE UAB RESEARCH FOUNDATION
    Inventors: William B. Parker, Eric J. Sorscher
  • Patent number: 10080785
    Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: September 25, 2018
    Assignee: NOVOZYMES BIOPHARMA DK A/S
    Inventors: David J. Ballance, Darrell Sleep, Christopher P. Prior, Homayoun Sadeghi, Andrew J. Turner
  • Patent number: 10080786
    Abstract: Improved formulations for transdermal delivery of botulinum toxin are disclosed. The formulations include, for example, botulinum toxin non-covalently associated with a positively charged backbone having branching or efficiency groups. The formulations also include a partitioning agent, oligo-bridge, or polyanion bridge, and may optionally contain a viscosity modifying agent. The formulations are designed for topical application onto the skin of a patient and may be used to treat wrinkles, hyperhidrosis, and other health-related problems. Kits for administration are also described.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: September 25, 2018
    Assignee: REVANCE THERAPEUTICS, INC.
    Inventors: Michael D Dake, Jacob M Waugh
  • Patent number: 10080787
    Abstract: Methods of capturing N-glycan linked glycomolecules including N-glycans, N-glycopeptides and N-glycoproteins are described. The methods provide substantially unbiased capture of charged and uncharged N-glycans and/or N-glycan linked glycomolecules. Binding reagents for substantially unbiased binding of N-glycans and/or N-glycan linked glycomolecules are also described.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: September 25, 2018
    Assignee: New England Biolabs, Inc.
    Inventors: Minyong Chen, Xiaofeng Shi, James C. Samuelson, Christopher H. Taron
  • Patent number: 10080788
    Abstract: Compositions and methods for the treatment and/or prevention of disorders associated with C1 esterase inhibitor deficiency are disclosed.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: September 25, 2018
    Assignee: Shire ViroPharma Incorporated
    Inventors: Stephen Ruddy, Mark Cornell Manning, Ryan Erik Holcomb
  • Patent number: 10080789
    Abstract: Biomaterial systems, e.g., gel scaffolds, are used in vivo to recruit immune cells and promote their activation towards a non-inflammatory phenotype, thereby leading suppression of inflammation. The compositions and methods are useful to reduce the severity of autoimmunity, chronic inflammation, allergy, and periodontal disease.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: September 25, 2018
    Assignees: President and Fellows of Harvard College, Forsyth Dental Infirmary for Children
    Inventors: Roger Warren Sands, Eduardo Alexandre Barros E Silva, Toshihisa Kawai, David J. Mooney
  • Patent number: 10080790
    Abstract: The disclosure generally relates to the field of prevention and treatment of Staphylococcus aureus infections. In particular, the disclosure relates to immunogens comprising Staphylococcus aureus antigens and methods for generating immune responses to immunogens, and to antibody products specific for the Staphylococcus aureus epitopes and methods for treating Staphylococcus aureus infection with the antibody products.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: September 25, 2018
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Jon Oscherwitz, Kemp Cease
  • Patent number: 10080791
    Abstract: The invention relates to hyperbaric devices for inactivating microorganisms and viruses while retaining their immunogenicity and for making and producing the soluble, disaggregated, refolded or active immunogenic or therapeutic proteins from inclusion bodies produced from prokaryotes or eukaryotes. The invention encompasses hyperbaric methods for inactivating pathogenic organisms, and methods for producing vaccine compositions using the inactivated pathogens. The hyperbarically inactivated microorganisms are safer and more immunogenic than chemically inactivated microorganisms. Similarly, the solubilized proteins have superior properties compared to more heavily aggregated proteins, including reduced non-specific immune reactions.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: September 25, 2018
    Assignee: MERIAL INC.
    Inventors: Nicolas Pierre Yves Carboulec, Rene Labatut, Lionel Gerentes
  • Patent number: 10080792
    Abstract: The present invention is directed generally to M1 polypeptides that can be utilized as vaccines and/or antigens for generation of anti-M1 polypeptide antibodies for prophylactic treatment of individuals who are susceptible to infection by influenza virus. The anti-M1 polypeptide antibodies of the invention are useful for treatment of individuals infected with influenza virus, or useful for prophylactic treatment of individuals who are susceptible to infection by influenza virus, or for immune-suppressed individuals who cannot generate an effective antibody response.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: September 25, 2018
    Assignee: EnGen Bio, Inc.
    Inventors: Mark Alfenito, Mark Baer, Doris Bucher, Geoffrey Yarranton
  • Patent number: 10080793
    Abstract: The present invention relates to a method for prevention and/or reduction of aggregation of viral components.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: September 25, 2018
    Assignee: De Staat der Nederlanden, vert, door de minister van VWS, Ministerie van Volksgezonheid, Welzijn en Sport
    Inventors: Arend Gesinus van't Oever, Wilfridus Adrianus Maria Bakker, Yvonne Elisabeth Thomassen
  • Patent number: 10080794
    Abstract: Disclosed are compositions and methods comprising vectors and a reverse genetics competent unit comprising one or more recombinant influenza viruses. Recombinant influenza viruses comprising swine RNA polymerase I promoter are disclosed. Constructs comprising swine RNA polymerase I promoter nucleic acid sequences are also provided. Methods of inducing protecting immunity with the recombinant influenza viruses are disclosed. In certain embodiments, the reverse genetics competent unit comprises pathogenic units necessary for producing pathogens de novo from a nucleotide-based vector for influenza virus in swine.
    Type: Grant
    Filed: March 15, 2014
    Date of Patent: September 25, 2018
    Assignee: UNIVERSITY OF MARYLAND, COLLEGE PARK
    Inventors: Daniel R. Perez, Matthew Angel
  • Patent number: 10080795
    Abstract: The invention relates to a method for inactivating viruses, characterized in that an immunogenic composition or vaccine comprising at least one virus is irradiated with electron beams, said immunogenic composition or vaccine comprising at least one virus (i) being liquid, in particular being a suspension and (ii) comprising at least one viral immunogen, wherein the antigen structure is preferably substantially retained.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: September 25, 2018
    Assignee: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.
    Inventors: Sebastian Ulbert, Christiane Wetzel
  • Patent number: 10080796
    Abstract: Described herein are influenza virus-like particles (VLPs) that display on truncated, re-engineered or remodeled HA molecules on their surface. Also described are methods of making and using these VLPs.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: September 25, 2018
    Assignee: TECHNOVAX, INC.
    Inventors: Jose M. Galarza, George R. Martin
  • Patent number: 10080797
    Abstract: Provided are an oncolytic heterologous recombinant Newcastle disease virus (NDV), preparation method and application thereof. The heterologous recombinant NDV can express alpha (1,3) galactosyltransferase (?1,3GT). The ?1,3GT is the protein represented by the flowing B1) and B2): B1) the protein has an amino acid sequence of SEQ ID No.1; and B2) the protein is derived from B1) and has a function of ?1,3GT obtained by substituting and/or deleting and/or adding one or more amino acid residue(s) in the amino acid sequence represented by SEQ ID No.1. The recombination NDV can be used for tumor treatment.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: September 25, 2018
    Inventor: Yongxiang Zhao
  • Patent number: 10080798
    Abstract: The present invention encompasses canine parvovirus (CPV) vaccines or compositions. The vaccine or composition may be a vaccine or composition containing CPV virus-like particle (VLP), and a preparation method and a use thereof. The CPV VLPs provided by the invention are formed by the CPV VP2 protein. Further, the invention broadly encompasses vaccines comprising combinations of MLV and VLP, which are capable of overcoming MDA against a variety of pathogens, which infect a variety of different species.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: September 25, 2018
    Assignee: MERIAL INC.
    Inventors: Frederic David, Zahia Hannas-Djebbara, Herve Poulet, Jules Maarten Minke
  • Patent number: 10080799
    Abstract: Disclosed herein are compositions and methods for eliciting immune responses against HCV antigens. In particular embodiments, the compounds and methods elicit immune responses against all or a segment of HCV glycoprotein E1 and/or HCV glycoprotein E2.
    Type: Grant
    Filed: February 11, 2011
    Date of Patent: September 25, 2018
    Assignee: Arizona Board of Regents on Behalf of Arizona State University
    Inventors: Hugh S. Mason, Seong Hee Bhoo, Sun Hee Rosenthal, Charles J. Arntzen
  • Patent number: 10080800
    Abstract: This invention relates to antibodies or fragments thereof which interact with HER family of receptors, e.g., HER3 receptor. In particular, it relates to antibodies or fragments thereof that recognize a conformational epitope of HER3 receptor comprising residues from both domains 2 and 4 resulting in inhibition of both ligand-dependent and ligand-independent signal transduction; and allow ligand binding (e.g., neuregulin), while preventing ligand-induced activation of signal transduction. These antibodies or fragments can be used to treat a number of diseases or disorders characterized by increased levels of HER3 expression (e.g., esophageal cancer). These antibodies or fragments can be used to treat a number of diseases or disorders characterized by the antibodys or fragments ability to decrease tissue weight (e.g., prostate or uterine weights) or to induce atrophy of tissue (e.g., atrophy of male breast).
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: September 25, 2018
    Assignee: Novartis AG
    Inventors: Winfried Elis, Seth Ettenberg, Andrew Paul Garner, Nicole Haubst, Xizhong Huang, Christian Carsten Silvester Kunz, Elizabeth Anne Reisinger Sprague, Qing Sheng
  • Patent number: 10080801
    Abstract: Pharmaceutical compositions and single unit dosage forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein. Also provided are methods of treating, managing, or preventing various disorders, such as cancer, an inflammatory disease and/or an immune-related disorder.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: September 25, 2018
    Assignee: Celgene Corporation
    Inventors: Darshan Parikh, Anil Menon
  • Patent number: 10080802
    Abstract: A granulation formulation of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide or pharmaceutically acceptable salt thereof, which is adapted for reconstitution with an aqueous vehicle, and associated oral suspension.
    Type: Grant
    Filed: January 13, 2016
    Date of Patent: September 25, 2018
    Assignee: Novartis AG
    Inventors: Gossett Augustus Campbell, Helen Richardson, Peter A. Williams
  • Patent number: 10080803
    Abstract: Oil-in-water emulsions are prepared using phospholipids purified from krill.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: September 25, 2018
    Assignee: Aker BioMarine Antartic AS
    Inventor: Stefan Hupfeld
  • Patent number: 10080804
    Abstract: Described is a conjugate of agent complex and at least one target-finding ligand, where the agent complex comprises an agent encapsulated by an encapsulation material and where the target-finding ligand is a prostacyclin analog, and the use of the conjugate.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: September 25, 2018
    Assignee: ETHRIS GMBH
    Inventors: Carsten Rudolph, Johannes-Peter Geiger
  • Patent number: 10080805
    Abstract: Conjugates are described herein where CCK2R targeting ligands are attached to an active moiety, such as therapeutic agent or an imaging agent, through a linker. The conjugates can be used in the detection, diagnosis, imaging and treatment of cancer.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: September 25, 2018
    Assignee: Purdue Research Foundation
    Inventors: Philip S. Low, Charity Wayua
  • Patent number: 10080806
    Abstract: Polythioaminal polymers are made from hexahydrotriazine precursors and dithiol precursors. The precursors are blended together and subjected to mild heating to make the polymers. The polymers have the general structure wherein each R1 is independently an organic or hetero-organic group, each R2 is independently a substituent having molecular weight no more than about 120 Daltons, X and Z are each a sulfur-bonded species, at least one of X and Z is not hydrogen, and n is an integer greater than or equal to 1. X and Z may be hydrogen or a functional group, such as a thiol-reactive group. The reactive thiol groups of the polythioaminal may be used to attach thiol-reactive end capping species. By using water soluble or water degradable dithiols, such as polyether dithiols, water soluble polythioaminals may be made. Some such polymers may be used to deliver therapeutics with non-toxic aqueous degradation products.
    Type: Grant
    Filed: August 19, 2015
    Date of Patent: September 25, 2018
    Assignee: International Business Machines Corporation
    Inventors: Dylan J. Boday, Willy Chin, Jeannette M. Garcia, James L. Hedrick, Xiyu Ke, Rudy J. Wojtecki, Yi Yan Yang
  • Patent number: 10080807
    Abstract: The present invention is based on a finding of an unexpected synergistic and safe combination of antineoplastic agents which when administered in combination provides greater efficacy than the single agents alone. Accordingly, a method of treating neoplasia in a subject in need of treatment is provided, by administering to the subject an amount of a prodrug of mitomycin C that yields a therapeutically effective amount of mitomycin C, in combination with an amount of a chemotherapeutic agent. In one embodiment, the prodrug of mitomycin C is a liposomal-prodrug of mitomycin C. Together, the prodrug of mitomycin C and chemotherapeutic agent provide a synergistic antineoplastic effect.
    Type: Grant
    Filed: June 9, 2015
    Date of Patent: September 25, 2018
    Assignees: Lipomedix Pharmaceuticals Ltd., Shaare Zedek Scientific Ltd.
    Inventors: Alberto Gabizon, Patricia Ohana, Hilary Shmeeda
  • Patent number: 10080808
    Abstract: This disclosure provides therapeutic compositions and methods for treating multiple sclerosis or a multiple sclerosis-related disorder in a subject in need thereof comprising administering an effective amount of an antigen-MHC-nanoparticle complex to the subject, wherein the antigen is a multiple sclerosis-related antigen.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: September 25, 2018
    Assignee: UTI LIMITED PARTNERSHIP
    Inventor: Pedro Santamaria
  • Patent number: 10080809
    Abstract: The invention relates to an artificial nucleic acid molecule comprising at least one 5?UTR element which is derived from a TOP gene, at least one open reading frame and optionally at least one 3?UTR element comprising a nucleic acid sequence which is preferably derived from the 3?UTR of a gene providing a stable mRNA, such as an albumin gene, or from a variant of the 3?UTR of a gene providing a stable mRNA. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and/or genetic vaccination.
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: September 25, 2018
    Assignee: CureVac AG
    Inventor: Andreas Thess
  • Patent number: 10080810
    Abstract: A method for testing, treating, and preventing delayed food allergies includes: receiving detailed symptom, medical, and dietary histories from a patient; formulating a combination of one or more food extracts at selected concentrations for sublingual administration over a trial period; determining whether the patient's symptoms have improved, worsened, or had no change, in response to the administration of the combination; and altering the combination in response to whether the patient's symptoms have improved, worsened, or not changed, so as to induce immune system food tolerance.
    Type: Grant
    Filed: August 12, 2014
    Date of Patent: September 25, 2018
    Inventor: John Shea
  • Patent number: 10080811
    Abstract: The present Invention relates to the monitoring of biological substances, such as non-invasive monitoring of such substances in animal, for examples biomarkers and metabolites. Specifically, the invention further relates to such monitoring using rare earth tagged marker compounds. The invention further relates to such monitoring using laser spectroscopy or Raman spectroscopy. The invention further relates to the use of such monitoring in disease states, such as stroke, neurological disorders and cardiovascular disorders.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: September 25, 2018
    Assignee: University of Leeds
    Inventors: Sikha Saha, Gin Jose, Animesh Jha
  • Patent number: 10080812
    Abstract: The present invention relates to a radioactive iodine-labeled pyrido[1,2-a]benzimidazole derivative compound represented by a definite general formula or a salt thereof, or a radiopharmaceutical comprising the same.
    Type: Grant
    Filed: February 24, 2016
    Date of Patent: September 25, 2018
    Assignees: KYOTO UNIVERSITY, NIHON MEDI-PHYSICS CO., LTD.
    Inventors: Hideo Saji, Masahiro Ono, Masafumi Ihara, Ikuya Seki
  • Patent number: 10080813
    Abstract: An apparatus for aseptic insertion includes a container, a first cover, and a second cover. The container includes a first compartment, a second compartment, and a detachable wall disposed between the first compartment and the second compartment. The first cover is sized and configured to attach to the first compartment and the second cover is sized and configured to attach to the container. The detachable wall may defined by a top portion, a portion of a first distal wall of the first compartment, and a portion of a second proximal wall of the second compartment. The detachable wall may be removably attached to the first cover by the top portion of the detachable wall.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: September 25, 2018
    Assignee: Ethicon LLC
    Inventors: Kevin D. Felder, Michael J. Stokes, Christopher B. Anderson, Frederick E. Shelton, IV, David C. Yates, John W. Willis, Ashvani K. Madan, Donna L. Korvick
  • Patent number: 10080814
    Abstract: A method of freshening the air or a surface is provided. The method comprises the steps of: providing a freshening composition, the freshening composition comprising a plurality of particles and a structurant system; and spraying the freshening composition in the form of a plurality of spray droplets, wherein the plurality of spray droplets have: a normalized D(90) value of less than 2.5, when sprayed from a TS800 sprayer according to the SPRAY D(90) NORMALIZED AND SPRAY D(4,3) NORMALIZED TEST METHOD described herein, a residue value of less than about 8 at 5 sprays, according to the RESIDUE TEST METHOD described herein, and a phase stability grade of 1 or 2, according to the PHASE STABILITY GRADE AT 25° C. TEST METHOD described herein.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: September 25, 2018
    Assignee: The Procter & Gamble Company
    Inventors: Matthew Lawrence Lynch, Carla Jean Colina, Steven Anthony Horenziak, Brandon Philip Illie, Yonas Gizaw
  • Patent number: 10080815
    Abstract: A system for diffusing one or more volatile compounds includes a base and a pod tray, carried by the base. At least one pod is carried by the pod tray. The pod has a housing holding a volatile compound mass, the housing and mass being moveable relative to one another. An actuator is carried by the base, the actuator being operable to engage the pod and move the housing and the volatile compound mass relative to one another. The pod and the actuator are positionable relative to one another such that one or both of the pod and the actuator can be positioned proximate to one another to enable the actuator to engage the pod and move the housing and the volatile compound mass relative to one another.
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: September 25, 2018
    Assignee: Henkel IP & Holding GmbH
    Inventors: Keith Cardinal, Kevin Hafer